Table A2A.

Summary of the PCV7 serotype-specific IgG responses ≥0.35 μg/ml following adjustment for eczema and atopy.

		Adjusted
Vaccine	Unadjusteda	IgE-eczema (at 12 months)	IgE-eczema (ever)	Atopy
PCV7–4	3.29 (1.08, 9.95); p = 0.035	3.27 (1.05, 10.19); p = 0.041	3.30 (1.09, 10.00); p = 0.035	3.47 (1.10, 10.96); p = 0.034
PCV7–6B	2.32 (0.72, 7.41); p = 0.157	3.04 (0.89, 10.35); p = 0.075	2.36 (0.73, 7.61); p = 0.149	2.43 (0.73, 8.09); p = 0.147
PCV7–9V	3.50 (1.11, 11.02); p = 0.032	4.07 (1.23, 13.49); p = 0.022	3.62 (1.14, 11.51); p = 0.030	4.27 (1.26, 14.43); p = 0.019
PCV7–14	NA	NA	NA	NA
PCV7–18C	2.41 (0.82, 7.10); p = 0.111	2.30 (0.76, 6.96); p = 0.142	2.44 (0.82, 7.23); p = 0.107	2.93 (0.92, 9.35); p = 0.069
PCV7–19F	4.46 (0.47, 42.51); p = 0.194	4.96 (0.50, 48.92); p = 0.170	4.48 (0.47, 42.76); p = 0.192	4.56 (0.46, 45.46); p = 0.196
PCV7–23F	5.21 (1.28; 21.24); p = 0.021	5.25 (1.25, 22.03); p = 0.024	5.21 (1.28, 21.24); p = 0.021	4.67 (1.12, 19.55); p = 0.035

Data represents the Odds Ratio and 95% confidence intervals; NA, not assessed due to co-linearity issues.

^a Unadjusted analysis after removing missing data for eczema and atopy variables (N = 30 LGG; N = 30 Placebo).